Clinical Trial

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-28; most recent amendment 2025-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06340750
Lead Sponsor Luminary Therapeutics
Collaborators: Nationwide Children's Hospital
Conditions Systemic Lupus Erythematosus
Enrollment 18 participants
Start Date 2025-04-01
Primary Completion 2026-04-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2025-06-03